•  
  •  
  •  
  •  

2025-10-02 05:00:36

  • Home
  • Commodities
  • Industry News
  • IPO
  • Mutual Funds
  • Others
  • Research
  • Watch List
Latest News
  • Hero MotoCorp Ltd dispatches 687,220 units in September 2025
  • Synbiotics Ltd's Amphotericin B Manufacturing Facility receives USFDA approval
  • Veefin has successfully integrated CRIF's Strategy One BRE with our no-code Digital Lending Stack
  • Sentynl Therapeutics updates on its NDA for CUTX-101
  • Unimech Aerospace and Manufacturing Ltd experiences slowdown in revenue

Keywords Selected:  Pharmaceuticals

Research

  • Kotak Institutional Equities - Pharmaceuticals: IPM pulse - gaining momentum
  • Company Update - P&G Health - ICICI Direct
  • Quant Pick - Cadila Healthcare - ICICI Direct
  • Q2FY22 Result Update - Syngene International - ICICI Direct
  • Syngene International Ltd - Lack of near term triggers - YES Securities
  • Syngene International Ltd - Lower gross margin lead to EBIDTA miss - YES Securities

IPO News

  • Accretion Pharmaceuticals' IPO Opens for subscription today, Price Band set at ₹96-101 per Share
  • Accretion Pharmaceuticals Ltd IPO to open for subscription on May 14, 2025
  • Senores Pharmaceuticals IPO subscribed 13.93 times on Day 2
  • Senores Pharmaceuticals IPO fully subscribed on Day 1
  • Senores Pharmaceuticals gets Sebi nod for IPO

Stock Report

  • Synbiotics Ltd's Amphotericin B Manufacturing Facility receives USFDA approval
  • Sentynl Therapeutics updates on its NDA for CUTX-101
  • Veerhealth Care Limited receives order for Hair Care and Oral Care products
  • Lupin Launches Rivaroxaban for Oral Suspension in the United States
  • Wockhardt Submits New Drug Application to U.S. FDA for Zidebactam-Cefepime for Treatment of Serious GramNegative Infections
  • Lupin receives approval from U.S. FDA for Rivaroxaban for Oral Suspension
  • Syschem India Ltd announces expansion, to set up new production unit
  • Lupin Strengthens its Global Specialty Ophthalmology Business with acquisition of VISUfarma from GHO Capital
  • Haleos Labs Limited successfully completes ANVISA audit at Unit-1
  • THE LANCET Regional Health publishes Pivotal Phase 3 Clinical Study on Miqnaf®
  • Alembic Pharmaceuticals Ltd announces USFDA Final Approval for Paroxetine Extended Release Tablets USP, 25 mg and 37.5 mg.
  • Glenmark Strengthens Oncology Portfolio with Hengrui's HER2 Targeting ADC For Multiple Regions
  • Jeena Sikho Lifecare Ltd commences new hospital at Raigad District
  • Fermenta Biotech Limited Certified as a Great Place to Work®
  • Relonchem Limited receives Marketing Authorization for its products
  • Shelter Pharma's Participation in AYUSH India Expo 2025
  • Zydus and Pinkathon join hands to drive awareness on breast cancer across India
  • Shilpa Medicare Ltd receives initial authorization for Rivaroxaban Orodispersible Films from Europe
  • Alkem launches Pertuza, a pertuzumab biosimilar, in India for treatment of HER2-positive breast cancer
  • Shelter Pharma Ltd installs 15 KW solar power plant
  • Jeena Sikho Lifecare Ltd's MD receives award from Atal Foundation
  • Zydus receives EIR for the oncology injectable manufacturing facility in SEZ1, Ahmedabad
  • Lupin gets 4 observations from USFDA from PAI at Pune Biotech facility
  • USFDA successfully completes inspection at Indoco's API manufacturing facility at Patalganga with zero observations

Industry News

  • NYSE Listed Amneal Pharmaceuticals begins Commercial Operations in India

Latest Post

  • Hero MotoCorp Ltd dispatches 687,220 units in September 2025
  • Synbiotics Ltd's Amphotericin B Manufacturing Facility receives USFDA approval
  • Veefin has successfully integrated CRIF's Strategy One BRE with our no-code Digital Lending Stack
  • Sentynl Therapeutics updates on its NDA for CUTX-101
  • Unimech Aerospace and Manufacturing Ltd experiences slowdown in revenue


Announcement

To Advertise in our website please e-mail us at advertisement@equitybulls.com
Companies can send their Press Releases to pressrelease@equitybulls.com

Links

  • Home
  • Contact
  • Our Team

Contact

The website is developed and maintained by Chennai Scripts
C-4, Podhigai Flats, Pillayar Koil Street, Nesapakkam
Chennai
Tamil Nadu
India
600078
E-mail: chennaiscripts@gmail.com
Mobile Phone Number: +91-88776-69935
www.chennaiscripts.com

Website Created & Maintained by : Chennai Scripts
Nesapakkam, Chennai - 600 078,
Tamil Nadu, India

Disclaimer Copyright © - 2024